Impact of Peri‐Procedural Antibiotics on Post‐ERCP Infectious Adverse Events With Distal Malignant Biliary Obstruction
Einfluss periinterventioneller Antibiotika auf infektiöse unerwünschte Ereignisse nach ERCP bei distaler maligner biliärer Obstruktion
Journal of Gastroenterology and Hepatology · 2026-02 · 41 (2) · 696-704
DOI: 10.1111/jgh.70211 ↗Auf einen Blick
Bei 508 Patient:innen mit distaler maligner biliärer Obstruktion war die Rate infektiöser Ereignisse nach ERCP unter peri-ERCP-Antibiotika niedriger als ohne Antibiotika.
Fragestellung
Welchen Einfluss haben peri-ERCP-Antibiotika auf infektiöse unerwünschte Ereignisse nach ERCP bei distaler maligner biliärer Obstruktion?
Methode
Multizentrische retrospektive Studie mit Propensity-Score-Matching an 5 Zentren; 508 Patient:innen mit initialer biliärer Stentanlage zwischen Januar 2020 und August 2024.
Ergebnisse
Nach Matching 165 Patient:innen je Gruppe. Infektiöse Ereignisse: 3,6 % mit Antibiotika vs. 10,3 % ohne; RD 6,7 % (95 %-KI 1,2–12,1). Pankreatitis: 6,1 % vs. 9,7 %; RD −3,6 % (95 %-KI −9,4 bis 2,2).
Schlussfolgerung der Autor:innen
Peri-ERCP-Antibiotika können infektiöse unerwünschte Ereignisse nach ERCP bei DMBO verringern.
Kernaussagen
- Infektiöse Ereignisse: 3,6 % mit Antibiotika vs. 10,3 % ohne
- RD 6,7 % (95 %-KI 1,2–12,1)
- Kein signifikanter Unterschied bei post-ERCP-Pankreatitis
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 29.12.2025. Verfasst von Tatsunori Satoh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shizuoka General Hospital, Shizuoka, Japan. Hauptthemen laut MEDLINE: Cholangiopancreatography, Endoscopic Retrograde, Cholangitis, Antibiotic Prophylaxis, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background and Aims Malignant biliary obstruction (MBO) often necessitates endoscopic retrograde cholangiopancreatography (ERCP) for biliary drainage. Although ERCP is the standard treatment, post‐procedural infections such as cholangitis and cholecystitis remain clinically important. Current guidelines recommend prophylactic antibiotics only for high‐risk cases. However, data focused specifically on patients with distal MBO (DMBO) undergoing stent placement are limited. This study evaluated the effect of peri‐ERCP antibiotics on post‐ERCP infectious adverse events in DMBO.
Methods
This multicenter retrospective study included 508 patients who underwent initial biliary stent placement for DMBO between January 2020 and August 2024 at five institutions. Patients were categorized according to whether they received peri‐ERCP antibiotics. Propensity score matching (1:1) was performed using clinically relevant covariates. The primary outcome was the incidence of infectious adverse events (cholangitis or cholecystitis) within 5 days of ERCP.
Results
After matching, 165 patients were included in each group. The incidence of infectious adverse events was significantly lower in the peri‐ERCP antibiotic group (3.6%) compared with the nonantibiotic group (10.3%), with a risk difference (RD) of 6.7% (95% confidence interval [CI]: 1.2–12.1). Post‐ERCP pancreatitis occurred in 10 patients (6.1%) without prophylaxis and 16 (9.7%) with prophylaxis, showing no significant difference (RD: −3.6%, 95% CI: −9.4 to 2.2). Subgroup analysis suggested greater benefit in patients with nonpancreatic cancer (RD, 0.206; 95% CI, 0.07–0.342; p = 0.011) or a bile duct diameter > 10 mm (RD, 0.104; 95% CI, 0.046–0.163; p = 0.001).
Conclusions
Peri‐ERCP antibiotics may reduce post‐ERCP infectious adverse events in patients with DMBO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Shizuoka General Hospital, Shizuoka, Japan.
- Research Support Center, Shizuoka General Hospital, Shizuoka, Japan.
- Department of Biostatistics and Health Data Science, Graduate School of Medical Science, Nagoya City University, Nagoya, Japan.
- Department of Gastroenterology, Seirei Hamamatsu General Hospital, Shizuoka, Japan.
- Division of Gastroenterology, Showa University Fujigaoka Hospital, Kanagawa, Japan.
- Department of Gastroenterology, Iwata City Hospital, Shizuoka, Japan.
ORCID-Profile: Fumitaka Niiya, Junichi Kaneko, Tetsushi Azami, Shinya Kawaguchi
Zitieren
APA
Satoh, T., Takahashi, H., Nakatani, E., Kobayashi, Y., Niiya, F., Kaneko, J., Ishikawa, K., Ito, K., Azami, T., Noda, J., & Kawaguchi, S. (2026). Impact of Peri‐Procedural Antibiotics on Post‐ERCP Infectious Adverse Events With Distal Malignant Biliary Obstruction. Journal of Gastroenterology and Hepatology, 41(2), 696-704. https://doi.org/10.1111/jgh.70211
Vancouver
Satoh T, Takahashi H, Nakatani E, Kobayashi Y, Niiya F, Kaneko J, et al. Impact of Peri‐Procedural Antibiotics on Post‐ERCP Infectious Adverse Events With Distal Malignant Biliary Obstruction. Journal of Gastroenterology and Hepatology. 2026;41(2):696-704. doi:10.1111/jgh.70211
BibTeX
@article{Satoh2026,
author = {Satoh, Tatsunori and Takahashi, Haruna and Nakatani, Eiji and Kobayashi, Yosuke and Niiya, Fumitaka and Kaneko, Junichi and Ishikawa, Kazuma and Ito, Kenta and Azami, Tetsushi and Noda, Jun and Kawaguchi, Shinya},
title = {Impact of Peri‐Procedural Antibiotics on Post‐ERCP Infectious Adverse Events With Distal Malignant Biliary Obstruction},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {2},
pages = {696--704},
doi = {10.1111/jgh.70211}
}
EUVIMED